Antibodies binding to anionic phospholipids but not to oxidized low-density lipoprotein are associated with thrombosis in patients with systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 14, Issue 5, 1996, Pages 499-506

  Aho, K ^a   Vaarala, O ^a   Tenkanen, L ^b   Julkunen, H ^c   Jouhikainen, T ^d   Alfthan, G ^a   Palosuo, T ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b Helsinki Heart Study   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d FINNISH RED CROSS BLOOD SERVICE   (Finland)

Author keywords

antiphospholipid antibodies; oxidized low density lipoprotein; systemic lupus erythematosus; thrombosis

Indexed keywords

LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIONS; BINDING SITES, ANTIBODY; CARDIOLIPINS; CORONARY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, LDL; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PHOSPHATIDYLSERINES; PHOSPHOLIPIDS; THROMBOSIS;

EID: 0029790017     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. HUGHES GRV: The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-4.
2. MCNEIL HP, CHESTERMAN CN, KRILIS SA: Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-208.
3. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
4. GALLI M, COMFURIUS P, MAASSEN C, HEMKER HC, DEBAETS MH, VAN BREDA-VRIESMAN PJC, BARBUI T, ZWAAL RFA, BEVERS EM: Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
5. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
6. 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 954-60.
7. ROUBEY RAS: Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994; 84: 2854-67.
8. HARRIS EN, PIERANGELI S: Anticardiolipin antibodies: specificity and function. Lupus 1994; 3: 217-22.
9. WITZTUM JL, STEINBERG D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92.
10. PARUMS DV, BROWN DL, MITCHINSON MJ: Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990; 114: 383-7.
11. ARMSTRONG VW, WIELAND E, DIEDRICH F, RENNER A, RATH W, KREUZER H, KUHN W, OELLERICH M: Serum antibodies to oxidised low-density lipoprotein in pre-eclampsia and coronary heart disease (letter). Lancet 1994; 343: 1570.
12. PUURUNEN M, MÄNTTÄRI M, MANNINEN V, TENKANEN L, ALETHAN G, EHNHOLM C, VAARALA O, AHO K, PALOSUO T: Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-9.
13. SALONEN JT, YLÄ-HERTTUALA S, YAMAMOTO R, BUTLER S, KORPELA H, SALONEN R, NYYSSÖNEN K, PALINSKI W, WITZTUM JL: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7.
14. VAARALA O, ALFTHAN G, JAUHIAINEN M, LEIRISALO-REPO M, AHO K, PALOSUO T: Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-5.
15. CRAIG WY, POULIN SE, NELSON CP, RITCHIE RF: ELISA of IgG antibody to oxidized low-density lipoprotein: Effects of blocking buffer and method of data expression. Clin Chem 1994; 40: 882-8.
16. VAARALA O, PUURUNEN M, LUKKA M, ALFTHAN G, LEIRISALO-REPO M, AHO K, PALOSUO T: Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidised low-density lipoprotein. Clin Exp Immunol 1996; 104: 269-74.
17. TAN EM, COHEN AS, FRIES JF, MASI AT, MCSHANE DJ, ROTHFIELD NF, SCHALLER JG, TALAL N, WINCHESTER RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
18. PALINSKI W, ROSENFELD ME, YLÄ-HERTTUALA S, GURTNER GC, SOCHER SA, BUTLER S, PARTHASARATHY S, CAREW TE, STEINBERG T, WITZTUM JL: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-6.
19. PALINSKI W, YLÄ-HERTTUALA S, ROSENFELD ME, BUTLER S, SOCHER SA, PARTHASARATHY S, CURTISS LK, WITZTUM JL: Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10: 325-35.
20. VAARALA O: Binding profiles of cardiolipin-binding antibodies in SLE and in infectious diseases. J Autoimmunity 1991; 4: 819-30.
21. JOUHIKAINEN T, JULKUNEN H, VAARALA O, LEIRISALO-REPO M, STEPHANSSON E, VAHTERA E, PALOSUO T, MYLLYLÄ G: Antiphospholipid antibodies and thrombosis in systemic lupus erythematosus: comparison of three lupus anticoagulant assays and anticardiolipin ELISA in 188 patients. Blood Coag Fibrinol 1992; 3: 407-14.
22. DIXON WJ (Ed.): BMDP Statistical Software Manual. Berkeley, University of California Press, 1990.
23. BRANCH DW, ROTE NS, DOSTAL DA, SCOTT JR: Association of lupus anticoagulant with antibody against phosphatidylserine. Clin Immunol Immunopathol 1987; 42: 63-75.
24. TRIPLETT DA, BRANDT JT, MUSGRAVE KA, ORR CA: The relationship between lupus anticoagulants and antibodies to phospholipids. JAMA 1988; 259: 550-4.
25. ROTE NS, DOSTAL-JOHNSON D, BRANCH DW: Antiphospholipid antibodies and recurrent pregnancy loss: Correlation between the activated partial thromboplastin time and antibodies against phosphatidyl serine and cardiolipin. Am J Obstet Gynecol 1990; 163: 575-84.
26. BAKER WF, BICK RL: Antiphospholipid antibodies in coronary artery disease: a review. Semin Thromb Hemost 1994; 20: 27-45.
27. VAARALA O, MÄNTTÄRI M, MANNINEN V, TENKANEN L, PUURUNEN M, AHO K, PALOSUO T: Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-7.
28. JONSSON H, NIVED O, STURFELT G: Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989; 68: 141-50.
29. PETRI M, PEREZ-GUTTHANN S, SPENCE D, HOCHBERG MC: Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-9.
30. ASHERSON RA, MACKAY JR, HARRIS EN: Myocardial infarction in a young man with systemic lupus erythematosus, deep vein thrombosis, and antibodies to phospholipid. Br Heart J 1986; 56: 190-3.
31. MAARAVI Y, RAZ E, GILON D, RUBINOW A: Cerebrovascular accident and myocardial infarction associated with anticardiolipin antibodies in a young woman with systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 853-5.
32. GINSBURG KS, LIANG MH, NEWCOMER L, GOLDHABER SZ, SCHUR PH, HENNEKENS CH, STAMPFER MJ: Anticardiolipin antibodies and the risk of ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002.
33. VERMYLEN J, ARNOUT J: Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J Lab Clin Med 1992; 120: 10-2.